Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Research & Development (2022 - 2025)

Historic Research & Development for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to $5.2 million.

  • TriSalus Life Sciences' Research & Development rose 2268.31% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year decrease of 3175.39%. This contributed to the annual value of $17.7 million for FY2024, which is 4071.39% down from last year.
  • Latest data reveals that TriSalus Life Sciences reported Research & Development of $5.2 million as of Q3 2025, which was up 2268.31% from $3.9 million recorded in Q2 2025.
  • Over the past 5 years, TriSalus Life Sciences' Research & Development peaked at $9.5 million during Q3 2023, and registered a low of $3.0 million during Q4 2024.
  • Over the past 4 years, TriSalus Life Sciences' median Research & Development value was $5.2 million (recorded in 2025), while the average stood at $5.5 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 9771.21% in 2023, then crashed by 6191.27% in 2024.
  • TriSalus Life Sciences' Research & Development (Quarter) stood at $6.3 million in 2022, then grew by 23.97% to $7.8 million in 2023, then tumbled by 61.91% to $3.0 million in 2024, then skyrocketed by 74.92% to $5.2 million in 2025.
  • Its Research & Development stands at $5.2 million for Q3 2025, versus $3.9 million for Q2 2025 and $3.3 million for Q1 2025.